Agios Pharmaceuticals Shares Drop 23% After Novo Nordisk's Sickle Cell Trial Results

Agios Pharmaceuticals (AGIO) shares fell 23% following Novo Nordisk's (NVO) announcement that its drug etavopivat outperformed Agios' mitapavit in key sickle cell endpoints. Novo Nordisk plans to seek FDA approval for etavopivat in late 2026, which threatens Agios' market potential for its sickle cell treatment.

By Lee Samaha · Motley Fool · April 20, 2026, 16:19 UTC

Tickers: $AGIO $NVO

Topics: competitor news FDA approval pharmaceuticals sickle cell treatment stock price drop

Read the full article at Motley Fool

More World news

Federal Court Orders Veterans Guardian to Pay Treble Damages to Disabled Veteran Class PR Newswire · November 12, 2026, 18:41 UTC
AIRO Group Holdings Reaffirms 2026 Revenue Growth Guidance Amid $200 Million Drone Backlog Seeking Alpha · November 12, 2026, 18:40 UTC
Nvidia CEO Jensen Huang Resigns Amid Personal Scandal, Raising Uncertainty for Open Source AI Strategy TechCrunch · November 12, 2026, 18:39 UTC
Vor Bio and RemeGen Expand Collaboration for Autoimmune Disease Therapy Seeking Alpha · November 12, 2026, 18:35 UTC
EnterpriseDB Hires CMRD Engineering Team to Strengthen Sovereign AI Governance PR Newswire · November 12, 2026, 18:36 UTC
Alliant Credit Union Executive Meredith Ritchie Named 2027 Chicago Titan 100 Honoree PR Newswire · November 12, 2026, 18:36 UTC
Fed's Schmid Argues Construction Productivity is Key to Housing Affordability Over Interest Rate Cuts Seeking Alpha · November 12, 2026, 18:33 UTC
PROG Holdings Reports 59% GMV Growth and Announces $100 Million Share Repurchase Program Motley Fool · November 12, 2026, 18:30 UTC
Corteva Shares Plunge Over Q3 Earnings Miss and Pricing Pressures Motley Fool · November 12, 2026, 18:31 UTC
Teekay Tankers Shares Decline Despite Q3 Earnings Beat and New Vessel Orders Seeking Alpha · November 12, 2026, 18:27 UTC